7月6日，晶泰控股盘中上涨5.95%，报8.37港元，成交额2.41亿港元。生命科学板块整体走强，药明合联涨5.83%，金斯瑞生物科技涨5.95%，药明康德涨3.14%，板块共振助推个股表现。
公司层面，7月2日晶泰控股授出约3498万份购股权及约868万个受限制股份单位，行使价7.48港元，彰显管理层激励信心；此前公司与国际知名药企达成超4亿美元AI药物发现战略合作，1亿美元股份回购计划自6月10日起持续实施，AI自主实验工作站落地中石化标志平台向材料科学领域拓展取得实质进展，多重利好持续催化。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.